Skip to main content
. Author manuscript; available in PMC: 2012 Jun 28.
Published in final edited form as: Br J Haematol. 2007 Dec 5;140(3):344–347. doi: 10.1111/j.1365-2141.2007.06920.x

Table I.

Baseline characteristics of the patient samples.

Number of samples (n) (all newly diagnosed AML)
Patients/specimens 49/57
With protein data 46/49
AHD 15
Prior cancers 12
Cytogenetics
 Diploid 24
 chr. 5/7 6
 Complex 8
 inv 16 1
 inv 9, t(6;9), +8, +21 5
 Non-evaluable/IM 5
FAB
 M0 6
 M1 3
 M2 12
 M4 14
 M5 7
 M6/M7 2
 Unknown 5

Samples used for mutation screening and protein expression. Fifty-seven samples from 49 patients, eight patients had specimens from blood and marrow. For 46 of 49 patients, protein expression data was available.

AML, acute myeloid leukaemia; AHD, antedecendent haematological disorder; FAB, French–American–British Classification; chr. 5/7, any abnormality of chromosome 5 or 7; +8/+21, trisomie 8 or 21; IM, insufficient metaphases.